# Clinical Study of Recombinant Novel Coronavirus Vaccine

> **NCT04466085** · PHASE2 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 900 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cell) low-dose group
- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cells) high-dose group
- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cells) placebo group

## Key facts

- **NCT ID:** NCT04466085
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-12
- **Primary completion:** 2020-10-22
- **Final completion:** 2021-12-15
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2020-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466085, "Clinical Study of Recombinant Novel Coronavirus Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04466085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*